Pablo Belmonte, Newmanbrain CEO, has given an interview to the radio station RADIO ELCHE (CADENA SER) in its current program «Hoy por Hoy» after receiving the award as the winning company of the V Innova eVIA Contest for its technology for biomedical use.
During the interview conducted by the journalist Cristina Medina, Pablo Belmonte describes how the idea of creating the Spin-Off Newmanbrain of the Miguel Hernández University came up. In adition details some functionalities and characteristics of the portable neuroimaging device fNIR BrainSpy 28 by Newmanbrain.
You can listen to the interview below:
You can also play the interview directly from the Radio Elche de la Cadena Ser website at the following link:
Newmanbrain has been awarded in the V edition of said awards, specifically in the category “SOCIAL AND HEALTH CARE“.
Pablo Belmonte (center), Newmanbrain CEO, collecting the prize as winner of the contest.
The spin-off of the Science Park of the Newmanbrain UMH is in luck. The company has been awarded in the V edition of the Innova eVIA awards, specifically in the category “Social and Health Care”. This company specializes in the development of software and hardware for biomedical use, mainly in the areas of neuroscience and biomedicine. The Innova eVIA Awards seek to recognize projects that offer innovative solutions based on the use of ICT and with applications in the field of health or healthcare.
Newmanbrain CEO, Pablo Belmonte, pointed out, this recognition is a great impulse to publicize the work of the company: “This award is the consolidation of our dream, which began several years ago with much effort and enthusiasm. It will allow us to give visibility to our project and make tangible the academic knowledge, an objective that we could not have achieved if it were not for the support received from the Research Group of the Physiology Department of the UMH, from the University itself as well as of our family. ”
The spin-off of the UMH Scientific Park has developed an innovative device with the name fNIR BrainSpy 28 for the analysis of brain activity: a portable system that uses nearby infrared technology (fNIR) to measure and record brain functions. This fNIR BrainSpy 28 device helps to relate the response to certain stimuli (affective, cognitive, etc.) with changes in cerebral blood flow that occurs during mental activity.
Newmanbrain is driven by the former director of the Institute of Neurosciences (IN), a mixed center between the UMH and the Higher Council for Scientific Research (CSIC), and professor emeritus of the UMH, Carlos Belmonte; by the director of the Department of Physiology of the UMH, Joaquín Ibáñez; by Pablo Belmonte and by Alejandro Méndez.
Once the pre-selection process is finished, the five finalist candidates who choose the prize of that category are the following:
CATEGORY “SOCIAL AND HEALTH CARE”:
“FAMILIADOSpresented by FAMILIADOS HEALTHTECH S.L.
“FIRST CALLpresented by FIRST SOFT S.L.
“HOME MEDICAL DISPENSER” presented by FAGOR HEALTHCARE
“NEWMANBRAIN”presented by NEWMANBRAIN
“RE-HUB”presented by BIOSENSING SOLUTIONS S.L.
The winning nominations will be announced at the awards ceremony that closes this year’s contest and will take place next April (venue still to be confirmed).
EL MUNDO newspaper, in its section of Society and Technology of the Valencian Community on April 1, 2019 and in its digital version as in paper, echoes the fNIR BrainSpy 28 device of Newmanbrain developed in the Science Park of the University Miguel Hermandez de Elche (UMH).
Pablo Belmonte, Newmanbrain CEO, describes, during the interview conducted by EL MUNDO, various features and properties that the fNIR BrainSpy 28 Newmanbrain device offers to evaluate a person’s cognitive or emotional functions in a simple and effective way.
Image made by El Mundo newspaper
Image made by El Mundo newspaper
You can read the integrated interview in the following link:
Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.
